You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for Express Mobile, Inc. v. Google LLC (W.D. Tex. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Express Mobile, Inc. v. Google LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Express Mobile, Inc. v. Google LLC (W.D. Tex. 2020)

Last updated: February 9, 2026

Litigation Summary and Analysis for Express Mobile, Inc. v. Google LLC | 6:20-cv-00804

Case Overview

Express Mobile, Inc. filed a patent infringement suit against Google LLC on April 7, 2020, in the U.S. District Court for the Western District of Texas. The complaint alleges Google infringed on patents related to website design and customization technology. The case number is 6:20-cv-00804.

Alleged Patent Rights and Claims

Express Mobile accuses Google of infringing three patents:

  • U.S. Patent No. 9,868,824 – focuses on systems for designing and customizing web content without requiring user coding.
  • U.S. Patent No. 10,423,349 – covers methods for integrating web design tools with content management systems.
  • U.S. Patent No. 10,842,725 – pertains to online platforms enabling dynamic content editing.

Express Mobile claims Google’s services, including Google Web Designer and Google Sites, incorporate technology that violates these patents.

Legal Procedural Status

  • Initial Filing: April 7, 2020.
  • Google’s Response: The company filed a motion to dismiss on July 16, 2020, arguing the patents are invalid and that Google’s products do not infringe.
  • Court Decisions:
    • On June 15, 2021, the court granted a partial summary judgment for Google, dismissing certain claims pertaining to the '824 patent.
    • The court denied Google’s motion to dismiss the remaining claims, allowing the case to proceed.

Patent Validity and Prior Art

Google challenged the patents’ validity, citing prior art references dating back to 2004-2010, including publicly available web development tools and content management systems.

  • The court acknowledged the existence of prior art but did not invalidate the patents. It concluded that genuine issues of fact remain unresolved regarding the patents’ novelty and non-obviousness.

Infringement and Defense

  • Express Mobile’s Position: The patents cover core aspects of Google’s online editing tools, which they argue implement patented systems and methods.
  • Google’s Defense: Google claims its products do not infringe and that the patents lack validity due to obviousness and prior art references.

Settlement and Ongoing Litigation

As of the latest update, no settlement has been reported. The case remains active, with scheduled trial dates pending. Both parties continue to exchange evidence, and additional motions are expected as the case advances.

Implications

This case highlights the ongoing tension in tech patent litigation over online content management. Patent owners like Express Mobile pursue enforcement against industry giants, asserting broad patent rights. Google’s defenses emphasize patent invalidity and non-infringement, common strategies in high-stakes patent disputes.

Patent and Industry Context

  • The patents at issue are part of a broader trend of patent assertions by small tech innovators against dominant platform providers.
  • Google has frequently faced similar suits in mobile and web technology, often resulting in licensing agreements or dismissed claims.

Key Court Dates

  • Motion to dismiss hearing: December 10, 2020.
  • Partial summary judgment: June 15, 2021.
  • Next pretrial conference: Scheduled for March 2023.
  • Trial date: TBA.

Strategic Considerations for Stakeholders

  • Patent holders should assess enforceability and prior art challenges early in litigation.
  • Tech companies must evaluate potential infringement risks and consider design-around strategies.
  • The case emphasizes the importance of clear patent claims and thorough prior art searches in patent prosecution.

Key Takeaways

  • Express Mobile claims Google infringes patents on web design technology.
  • The court dismissed some claims but allowed residual infringement claims to proceed.
  • Google challenges patent validity based on prior art, a common defense.
  • The case exemplifies patent disputes in the web content management space.
  • Pending court dates suggest the matter could go to trial or settlement in 2023.

FAQs

1. What are the patents involved in this case?
The patents cover online web content design and customization systems, with U.S. Patent Nos. 9,868,824, 10,423,349, and 10,842,725.

2. Has the court invalidated any of these patents?
No. The court recognized prior art but did not invalidate the patents. The validity remains contested.

3. What is the main legal argument from Google?
Google asserts its products do not infringe the patents and that the patents are invalid due to obviousness and prior art.

4. Are there any settlement prospects?
No public settlement has been announced. Both sides continue litigation preparations, with trial dates pending.

5. How does this case relate to broader industry trends?
It exemplifies patent assertions by smaller tech firms against industry giants seeking to protect software and content management innovations.


References

[1] United States District Court for the Western District of Texas, Case No. 6:20-cv-00804.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.